Clinical outcomes of a real‐world prospective study using Dexcom ONE continuous glucose monitoring in people with diabetes treated with two or more insulin injections per day
Authors' conclusion
Real-world Dexcom ONE use was associated with clinically significant reductions in mean HbA1c after 6 months, along with meaningful improvements in participant-reported outcomes. CGM-derived outcomes also improved, with the possibility of there being greater improvement than could be captured in this study. These findings support expanding access to this real-time CGM system.
Study context
- Population
- Adults with suboptimally controlled T1D or T2D taking two or more insulin injections per day, initiating Dexcom ONE CGM, receiving usual diabetes careenrolled
- Participants
- 110 adults
- Exposure
- Before vs after 6 months of Dexcom ONE CGM use
- T1Dn = 34
- T2Dn = 76
- Outcome
- Change in HbA1c
- Follow-up
- 6 months
Methodological detailssingle-site, real-world
- Single-site
- Real-world
Main finding
As reported in the abstract
Change
−12 mmol/mol
P < 0.001
T1D: 6 months vs T1D: baseline · from 90 mmol/mol (10.3%) to 79 mmol/mol (9.4%)
Change
−18 mmol/mol
P < 0.001
T2D: 6 months vs T2D: baseline · from 86 mmol/mol (10.1%) to 67 mmol/mol (8.3%)
Observational data: associations, not effects.
Further findings
Participant-reported outcomes · 6 months
- Perception of health and diabetes distress improved in both groups
CGM-derived outcomes
- T2D: clinically meaningful increase in TIR
- + 9.0%
- T1D: modest improvement in TBR
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →